Bausch Health Companies Inc. Goodwill, Acquired During Period
Bausch Health Companies Inc. (BHC) reported Goodwill, Acquired During Period of $5.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Goodwill and Other
us-gaap:GoodwillAcquiredDuringPeriod · last filed 2026-07-30
- Bausch Health Companies Inc. goodwill, acquired during period for the quarter ending 2026-06-30 was $5.00M.
- Bausch Health Companies Inc. goodwill, acquired during period for the quarter ending 2026-03-31 was $0.00.
- Bausch Health Companies Inc. goodwill, acquired during period for the quarter ending 2024-12-31 was $27.00M.
- Bausch Health Companies Inc. goodwill, acquired during period for the quarter ending 2023-12-31 was $0.00.
- Bausch Health Companies Inc. goodwill, acquired during period for fiscal 2024 was $29.00M, a 6.45% decline from fiscal 2023.
- Bausch Health Companies Inc. goodwill, acquired during period for fiscal 2023 was $31.00M, a 520.00% increase from fiscal 2022.
- Bausch Health Companies Inc. goodwill, acquired during period for fiscal 2022 was $5.00M.
- Bausch Health Companies Inc. goodwill, acquired during period for fiscal 2016 was $1.00M, a 99.99% decline from fiscal 2015.
| Period end | Goodwill, Acquired During Period 3 month | Goodwill, Acquired During Period 6 month | Goodwill, Acquired During Period 9 month | Goodwill, Acquired During Period 12 month | Goodwill, Acquired During Period 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $5.00M 10-Q · filed 2026-07-30 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-04-30 | ||||
| 2025-12-31 | $119.00M 10-Q · filed 2026-07-30 | ||||
| 2024-12-31 | $27.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $29.00M 10-K · filed 2026-02-19 | |||
| 2024-09-30 | $2.00M 10-Q · filed 2024-10-31 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $23.00M derived: sum of 2 quarters · filed 2025-02-20 | $29.00M derived: sum of 3 quarters · filed 2025-02-20 | $31.00M 10-K · filed 2025-02-20 | |
| 2023-09-30 | $23.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $29.00M derived: sum of 2 quarters · filed 2023-11-02 | $31.00M 10-Q · filed 2023-11-02 | ||
| 2023-06-30 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $8.00M 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $2.00M 10-Q · filed 2023-05-04 | ||||
| 2022-12-31 | $5.00M 10-K · filed 2024-02-22 | ||||
| 2019-12-31 | $0.00 derived: 8-K 12 month − 10-Q 9 month · filed 2022-05-11 | $0.00 derived: sum of 2 quarters · filed 2022-05-11 | $0.00 derived: sum of 3 quarters · filed 2022-05-11 | $3.00M 8-K · filed 2022-05-11 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $0.00 derived: sum of 2 quarters · filed 2019-11-04 | $3.00M 10-Q · filed 2019-11-04 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $3.00M 10-Q · filed 2019-08-06 | |||
| 2019-03-31 | $3.00M 10-Q · filed 2019-05-06 | ||||
| 2016-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | $300.00K derived: sum of 2 quarters · filed 2019-02-20 | $300.00K derived: sum of 3 quarters · filed 2019-02-20 | $1.00M 10-K · filed 2019-02-20 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $0.00 derived: sum of 2 quarters · filed 2016-11-09 | $700.00K 10-Q · filed 2016-11-09 | $1.23B derived: sum of 4 quarters · filed 2017-03-01 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $700.00K 10-Q · filed 2016-08-09 | $1.23B derived: sum of 3 quarters · filed 2017-03-01 | $1.44B derived: sum of 4 quarters · filed 2017-03-01 | |
| 2016-03-31 | $700.00K 10-Q · filed 2016-06-07 | $1.23B derived: sum of 2 quarters · filed 2017-03-01 | $1.44B derived: sum of 3 quarters · filed 2017-03-01 | $9.41B derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-12-31 | $1.23B derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $1.44B derived: sum of 2 quarters · filed 2017-03-01 | $9.41B derived: sum of 3 quarters · filed 2017-03-01 | $9.46B 10-K · filed 2017-03-01 | $9.46B 10-K · filed 2016-04-29 |
| 2015-09-30 | $209.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-26 | $8.19B derived: sum of 2 quarters · filed 2015-10-26 | $8.24B 10-Q · filed 2015-10-26 | $8.33B derived: sum of 4 quarters · filed 2016-04-29 | |
| 2015-06-30 | $7.98B derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-28 | $8.03B 10-Q · filed 2015-07-28 | $8.12B derived: sum of 3 quarters · filed 2016-04-29 | $8.33B derived: sum of 4 quarters · filed 2016-04-29 | |
| 2015-03-31 | $50.80M 10-Q · filed 2015-04-30 | $141.00M derived: sum of 2 quarters · filed 2016-04-29 | $350.40M derived: sum of 3 quarters · filed 2016-04-29 | $359.10M derived: sum of 4 quarters · filed 2016-04-29 | |
| 2014-12-31 | $90.20M derived: 10-K 12 month − 10-Q 9 month · filed 2016-04-29 | $299.60M derived: sum of 2 quarters · filed 2016-04-29 | $308.30M derived: sum of 3 quarters · filed 2016-04-29 | $411.30M 10-K · filed 2016-04-29 | $396.30M 10-K · filed 2015-02-25 |
| 2014-09-30 | $209.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-24 | $218.10M derived: sum of 2 quarters · filed 2014-10-24 | $321.10M 10-Q · filed 2014-10-24 | $305.50M derived: sum of 4 quarters · filed 2015-02-25 | |
| 2014-06-30 | $8.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-01 | $111.70M 10-Q · filed 2014-08-01 | $96.10M derived: sum of 3 quarters · filed 2015-02-25 | $4.49B derived: sum of 4 quarters · filed 2015-02-25 | |
| 2014-03-31 | $103.00M 10-Q · filed 2014-05-09 | $87.40M derived: sum of 2 quarters · filed 2015-02-25 | $4.48B derived: sum of 3 quarters · filed 2015-02-25 | $4.66B derived: sum of 4 quarters · filed 2015-02-25 | |
| 2013-12-31 | -$15.60M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | $4.38B derived: sum of 2 quarters · filed 2015-02-25 | $4.56B derived: sum of 3 quarters · filed 2015-02-25 | $4.60B 10-K · filed 2015-02-25 | $4.60B 10-K · filed 2014-02-28 |
| 2013-09-30 | $4.39B derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-01 | $4.58B derived: sum of 2 quarters · filed 2013-11-01 | $4.61B 10-Q · filed 2013-11-01 | $5.95B derived: sum of 4 quarters · filed 2014-02-28 | |
| 2013-06-30 | $181.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | $217.19M 10-Q · filed 2013-08-07 | $1.55B derived: sum of 3 quarters · filed 2014-02-28 | $1.59B derived: sum of 4 quarters · filed 2014-02-28 | |
| 2013-03-31 | $35.65M 10-Q · filed 2013-05-03 | $1.37B derived: sum of 2 quarters · filed 2014-02-28 | $1.41B derived: sum of 3 quarters · filed 2014-02-28 | $1.50B derived: sum of 4 quarters · filed 2014-02-28 | |
| 2012-12-31 | $1.34B derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $1.37B derived: sum of 2 quarters · filed 2014-02-28 | $1.46B derived: sum of 3 quarters · filed 2014-02-28 | $1.52B 10-K · filed 2014-02-28 | |
| 2012-09-30 | $37.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05 | $123.17M derived: sum of 2 quarters · filed 2012-11-05 | $179.49M 10-Q · filed 2012-11-05 | $403.99M derived: sum of 4 quarters · filed 2013-02-28 | |
| 2012-06-30 | $85.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $141.93M 10-Q · filed 2012-08-03 | $366.43M derived: sum of 3 quarters · filed 2013-02-28 | $560.71M derived: sum of 4 quarters · filed 2013-02-28 | |
| 2012-03-31 | $56.32M 10-Q · filed 2012-05-04 | $280.82M derived: sum of 2 quarters · filed 2013-02-28 | $475.10M derived: sum of 3 quarters · filed 2013-02-28 | ||
| 2011-12-31 | $224.50M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $418.78M derived: sum of 2 quarters · filed 2013-02-28 | $596.33M 10-K · filed 2013-02-28 | ||
| 2011-09-30 | $194.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $371.83M 10-Q · filed 2011-11-04 | |||
| 2011-06-30 | $177.54M 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |